Part 1: Emerging Role of the Hepatic Thyroid Hormone Pathway in the Pathophysiology of NASH as presented at EASL ‘23: Welcome and Introduction with Prof Michael Trauner

Part 2: Emerging Role of the Hepatic Thyroid Hormone Pathway in the Pathophysiology of NASH as presented at EASL ‘23: NASH: A Growing Unmet Therapeutic Need with Prof Jörn Schattenberg

Part 3: Emerging Role of the Hepatic Thyroid Hormone Pathway in the Pathophysiology of NASH as presented at EASL ‘23: The Underestimated Importance of Thyroid Hormone Pathway in the Pathophysiology of NASH with Prof Meena Bansal, MD

Part 4: Emerging Role of the Hepatic Thyroid Hormone Pathway in the Pathophysiology of NASH as presented at EASL ‘23: Closing with Prof Michael Trauner

NASH Patient Identification, Referral and Management in Endocrinology and Hepatology Practices with Scott Isaacs, MD, FACE, FACP and Barton Isaac, PharmD

Part 1: Disease Overview of Nonalcoholic Steatohepatitis (NASH): The Active, Progressive Form of Nonalcoholic Fatty Liver Disease (NAFLD): Introduction with Keith Miller, PhD

Part 2: Disease Overview of Nonalcoholic Steatohepatitis (NASH): The Active, Progressive Form of Nonalcoholic Fatty Liver Disease (NAFLD): Definitions and Epidemiology; Pathophysiology; Natural History of the Disease; Morbidity and Mortality with Christina Hanson, MS, FNP

Part 3: Disease Overview of Nonalcoholic Steatohepatitis (NASH): The Active, Progressive Form of Nonalcoholic Fatty Liver Disease (NAFLD): Identifying Risk Factors; Patient Identification; Patient Perspective with Ann Moore, FNP-C